Recently, in 44 melanoma patients treated with Keytruda, scientists found that among the 21 patients who responded to treatment, the level of exosome PD-L1 in the blood before treatment was significantly lower than the level of exosome PD-L1 of the other 23 patients who did not respond to treatment. Here, CD274 is linked to melanoma.